美国药企艾伯维周三表示，作为一项超过1.2亿英镑（约1.61亿美元）投资的一部分，该公司已扩建其位于英国牛津的研发设施。
AbbVie has expanded its UK research and development facility in Oxford as part of a more than £120 million ($161 million) investment, the US drugmaker said on Wednesday.
这项投资是在美英敲定一项旨在根据特朗普总统的新美国定价政策提高英国药价的协议几个月后宣布的。以下是更多细节：这座占地12,000平方英尺的新设施名为“艾伯维牛津”，将拓宽其在免疫学、神经科学和肿瘤学领域的研究能力。该设施建立在2022年收购牛津生物技术公司DJS Antibodies所获得能力的基础之上。
The investment comes a few months after the US and Britain finalised an agreement aimed at increasing UK medicine prices in line with President Donald Trump's new US pricing policies. Here are more details:
这项投资将支持专注于确定新疾病靶点和联合疗法的研究，重点关注存在重大未满足医疗需求的领域。艾伯维每年与英国100多所大学和研究机构合作，并正在扩大与学术机构的合作，包括牛津大学。其中一项与牛津大学的合作正在研究某些炎症性疾病患者在疾病过程中对治疗的反应，旨在帮助指导未来的药物开发。艾伯维在其位于牛津、梅登黑德和马洛的英国业务中雇佣了1,100多名员工。
The new 12,000-square-foot site, known as AbbVie Oxford, will broaden its research capabilities across immunology, neuroscience and oncology The facility builds on capabilities gained through the 2022 acquisition of Oxford-based biotechnology company DJS Antibodies The investment will support research focused on identifying new disease targets and combination therapies in areas with significant unmet medical need AbbVie works with more than 100 universities and research organisations in the UK each year and is expanding collaborations with academic institutions, including the University of Oxford One collaboration with the University of Oxford is studying how patients with certain inflammatory diseases respond to treatments over the course of their illness, aiming to help guide future drug development AbbVie employs more than 1,100 people across its UK operations in Oxford, Maidenhead and Marlow